SC 13D/A
Beneficial Ownership Report
Eloxx Pharmaceuticals, Inc. Filed Acc 0001062993-24-015470
Stakes reported in this filing
| Reporting person | Shares | Of the class |
|---|---|---|
| Advent Life Sciences LLP | 124,972 | 3.98% |
| Advent Life Sciences Fund II LP | 124,972 | 3.98% |
| Rajesh Parekh | 124,972 | 3.98% |
| Shahzad Malik | 124,972 | 3.98% |
| Kaasim Mahmood | 124,972 | 3.98% |
| Dominic Schmidt | 124,972 | 3.98% |
Members of a group can each report the same shares, so these rows overlap and don't add up.
Stake history · largest stake in each 13D and 13G
- 2026-11-13 SCHEDULE 13G/A · Coastlands Capital LP 9.99%
- 2026-06-05 SCHEDULE 13G/A · Domicilium Capital Partners LLC 4.9%
- 2024-08-20 SC 13D/A · Advent Life Sciences LLP 3.98%
- 2023-02-13 SC 13G/A · Roche Finance Ltd 0.1%
- 2022-02-14 SC 13G/A · Roche Finance Ltd 5.8%
- 2022-02-03 SC 13D/A · LSP V Coöperatieve U.A 3.4%
- 2021-06-29 SC 13G · Gurnet Point L.P. 5.7%
- 2021-06-14 SC 13G · Roche Finance Ltd 5.3%
- 2021-05-21 SC 13D/A · Pontifax Management 4 G.P. (2015) Ltd. 8.66%
Loading formsc13da.htm…